

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1, 2, 5-7, 9, 11 and 21-25 are presently pending.

Please cancel claims 21, 22 and 25;

Please add new claim 27.

Listing of Claims:

Claim 1 (currently amended): A medical device [comprising] consisting essentially of a site-specific delivery device for the controlled release of at least one peroxisome proliferator-activated receptor gamma (PPAR γ) agonist and at least one biocompatible polymer.

Claim 2 (previously presented): The medical device according to claim 1 wherein said PPAR γ agonist is rosiglitazone.

Claim 3 (canceled)

Claim 4 (canceled)

Claim 5 (currently amended): The medical device according to any of claims 1 or 2 ~~or 4~~ wherein said medical device is a stent.

Claim 6 (original): The medical device according to claim 5 wherein said stent is a vascular stent or biliary stent.

Claim 7 (currently amended): The medical device according to claim 6 wherein said vascular stent is provided with a coating [comprising] consisting essentially of rosiglitazone and at least one biocompatible polymer.

Claim 8 (canceled)

Claim 9 (currently amended): The medical device according to claim 1 wherein said [coating further contains a] biocompatible polymer is selected from the group consisting of

polyvinyl pyrrolidone, polytetrafluoroethylene, poly-L-lactic acid, polycaprolactone, polyethylene glycol, polystyrene, acrylates, polyesters and mixtures thereof.

Claim 10 (canceled)

Claim 11 (currently amended): A medical device [comprising a stent having a coating comprising] consisting essentially of a vascular stent and rosiglitazone; and

a polymer selected from the group consisting of polyvinyl pyrrolidone, polytetrafluoroethylene, poly-L-lactic acid, polycaprolactone, polyethylene glycol, polystyrene, acrylates, polyesters and mixtures thereof.

Claims 12-22 (canceled)

Claim 23 (withdrawn): The medical device according to claim 22 wherein said antisense oligonucleotide is an anti-c-myc oligonucleotide.

Claim 24 (withdrawn): The medical device according to claim 22 wherein said chaperone inhibitor is geldanamycin.

Claim 25 (canceled)

Claim 26 (canceled)

Claim 27 (new): The medical device according to claim 7 wherein said biocompatible polymer is selected from the group consisting of polyvinyl pyrrolidone, polytetrafluoroethylene, poly-L-lactic acid, polycaprolactone, polyethylene glycol, polystyrene, acrylates, polyesters and mixtures thereof.